Extent of Resection and Quality Metrics in Lung Cancer Care: From the Patient Level to the Programmatic Level

All of the relevant financial relationships listed for these individuals have been mitigated. Unless otherwise noted, speakers have nothing to disclose.

Moderators

Anna McGuire, MD, MSc, FRCSC
Timothy Mullett, MD, MBA, FACS

Presentations

  1. ABTS Update
    Malcolm M. DeCamp, Jr., MD
    Disclosure(s): Pulmonx: Consultant (Ongoing)
     
  2. Wedge Resection: Current State and Importance of Quality
    Seth B. Krantz, MD
    Disclosure(s): Medtronic: Consultant (Terminated, July 10, 2024); Intuitive Surgical: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); NovaScan: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)
     
  3. Technical Considerations for High-Quality Wedge Resection
    Brendon Stiles, MD
    Disclosure(s): Arcus Biosciences: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing); BMS Foundation: Consultant (Ongoing); Bristol Myers Squib: Consultant (Ongoing); Gala Therapeutics: Consultant (Ongoing); Genentech: Consultant (Ongoing); Medtronic: Consultant (Ongoing); Pfizer: Consultant (Ongoing)
     
  4. Debate: Wedge
    Chi-Fu Jeffrey Yang, MD
    Disclosure(s): AstraZeneca: Advisory Board (Ongoing); Genentech: Advisory Board (Ongoing)
     
  5. Debate: Segment
    Harmik J. Soukiasian, MD
    Disclosure(s): DaVinci Intuitive Surgical: Speaker (Ongoing)
     
  6. Discussion
     
  7. Sublobar Resection Is Associated with Decreased Overall Survival in Stage I Non-Small Cell Lung Cancer with Tumor Spread Through Air Spaces
    Brittany Walker, BS
     
  8. Debate: 3 + 1 Nodal Stations at Time of Sublobar Resection is the Way to Go
    David D. Odell, MD, MMSc
     
  9. Debate: We Should Not be Using 3 +1 Nodal Stations
    Raja Flores, MD
     
  10. Discussion
     
  11. Impact of Frozen Section Pathology Examination of Surgical Margins in Sublobar Pulmonary Resections for Clinical Stage IA NSCLC
    Belisario A. Ortiz, MD
     
  12. What’s a “Quality Program?” Defining Metrics, Identifying Deficiencies, Implementing Change
    Lisa M. Brown, MD, MAS
     
  13. Discussion
Activity summary
Available credit: 
  • 2.25 ABS Accredited CME
  • 2.25 ABTS Accredited CME
  • 2.25 AMA PRA Category 1 Credit™
Activity opens: 
03/01/2025
Activity expires: 
03/01/2028
Cost:
$0.00
Part of: 
2025 STS Annual Meeting Online: General Thoracic Track
Rating: 
0

Available Credit

  • 2.25 ABS Accredited CME
  • 2.25 ABTS Accredited CME
  • 2.25 AMA PRA Category 1 Credit™

Price

Cost:
$0.00
Please login or register to take this course.

All of the relevant financial relationships listed for these individuals have been mitigated. Unless otherwise noted, speakers have nothing to disclose.

Moderators

Anna McGuire, MD, MSc, FRCSC
Timothy Mullett, MD, MBA, FACS

Presentations

  1. ABTS Update
    Malcolm M. DeCamp, Jr., MD
    Disclosure(s): Pulmonx: Consultant (Ongoing)
     
  2. Wedge Resection: Current State and Importance of Quality
    Seth B. Krantz, MD
    Disclosure(s): Medtronic: Consultant (Terminated, July 10, 2024); Intuitive Surgical: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); NovaScan: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)
     
  3. Technical Considerations for High-Quality Wedge Resection
    Brendon Stiles, MD
    Disclosure(s): Arcus Biosciences: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing); BMS Foundation: Consultant (Ongoing); Bristol Myers Squib: Consultant (Ongoing); Gala Therapeutics: Consultant (Ongoing); Genentech: Consultant (Ongoing); Medtronic: Consultant (Ongoing); Pfizer: Consultant (Ongoing)
     
  4. Debate: Wedge
    Chi-Fu Jeffrey Yang, MD
    Disclosure(s): AstraZeneca: Advisory Board (Ongoing); Genentech: Advisory Board (Ongoing)
     
  5. Debate: Segment
    Harmik J. Soukiasian, MD
    Disclosure(s): DaVinci Intuitive Surgical: Speaker (Ongoing)
     
  6. Discussion
     
  7. Sublobar Resection Is Associated with Decreased Overall Survival in Stage I Non-Small Cell Lung Cancer with Tumor Spread Through Air Spaces
    Brittany Walker, BS
     
  8. Debate: 3 + 1 Nodal Stations at Time of Sublobar Resection is the Way to Go
    David D. Odell, MD, MMSc
     
  9. Debate: We Should Not be Using 3 +1 Nodal Stations
    Raja Flores, MD
     
  10. Discussion
     
  11. Impact of Frozen Section Pathology Examination of Surgical Margins in Sublobar Pulmonary Resections for Clinical Stage IA NSCLC
    Belisario A. Ortiz, MD
     
  12. What’s a “Quality Program?” Defining Metrics, Identifying Deficiencies, Implementing Change
    Lisa M. Brown, MD, MAS
     
  13. Discussion